PPA
CRNX

Parametric Portfolio Associates’s Crinetics Pharmaceuticals CRNX Stock Holding History

Parametric Portfolio Associates’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$1.16M Buy
52,656
+39,096
+288% +$791K ﹤0.01% 2714
2021
Q4 		$385K Buy
13,560
+1,537
+13% +$37.9K ﹤0.01% 3176
2021
Q3 		$253K Buy
+12,023
New +$252K ﹤0.01% 3365

Other funds holding CRNX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Parametric Portfolio Associates's CRNX Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Crinetics Pharmaceuticals (CRNX) stake by 288% in Q1 2022, buying an estimated $791K and bringing the position to 52,656 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2714.

Parametric Portfolio Associates first reported a position in CRNX in Q3 2021 and has held it in 3 quarters since. 117 funds tracked by Wall St. Rank hold CRNX as of Q1 2022.

  • Parametric Portfolio Associates held 52,656 shares of Crinetics Pharmaceuticals worth $1.16M as of Q1 2022.
  • Parametric Portfolio Associates bought 39,096 Crinetics Pharmaceuticals shares in Q1 2022, an estimated $791K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2714 holding.
  • Parametric Portfolio Associates first reported a position in Crinetics Pharmaceuticals in Q3 2021 and has held it in 3 quarters since.
  • 117 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.